The Children’s Hospital of Philadelphia and Pfizer, Inc., the world’s largest research-based pharmaceutical company, are joining forces with the goal of translating biomedical discoveries into novel treatments. Children’s Hospital is set join the Centers for Therapeutic Innovation (CTI) network, a novel collaboration model built by Pfizer that brings academic researchers together with Pfizer scientists to expedite the pace of innovation.
Children’s Hospital is only the second pediatric center to participate in the CTI network, which has established partnerships with 21 academic medical centers throughout the United States, such as Rockefeller University, Beth Israel Deaconess Medical Center, and the University of California, San Francisco.
“We are excited to have this opportunity to accelerate the process of moving scientific insights toward therapies that healthcare providers can offer in the clinic,” said Philip R. Johnson, MD, chief scientific officer and executive vice president of The Children’s Hospital of Philadelphia Research Institute.
The goal is of the partnership is to advance a project into a Phase 1 clinical trial.
“This partnership will bring together the leading science at The Children’s Hospital of Philadelphia with Pfizer’s global capabilities,” said Jose Carlos Gutierrez-Ramos, PhD, senior vice president, Head of Biotherapeutics R&D at Pfizer. “Together, we increase the potential to bring novel medicines to patients.”
To read more about the CHOP-Pfizer collaboration, see the full press release.